132 related articles for article (PubMed ID: 38537866)
1. The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
Li R; Sarin S
Clin Res Hepatol Gastroenterol; 2024 May; 48(5):102323. PubMed ID: 38537866
[TBL] [Abstract][Full Text] [Related]
2. Advanced chronic renal disease is an independent risk factor for inpatient mortality following transjugular intrahepatic portosystemic shunt procedure.
Li R; Sarin S
Eur J Gastroenterol Hepatol; 2024 Mar; 36(3):332-337. PubMed ID: 38179873
[TBL] [Abstract][Full Text] [Related]
3. Disparity Among African Americans in Transjugular Intrahepatic Portosystemic Shunt Procedure: A National Inpatient Sample Analysis from 2015 to 2020.
Li R; Sarin S
Dig Dis Sci; 2024 Mar; 69(3):713-719. PubMed ID: 38319431
[TBL] [Abstract][Full Text] [Related]
4. Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020.
Li R; Luo Q; Yanavitski M; Huddleston SJ
Cardiovasc Revasc Med; 2024 May; 62():21-26. PubMed ID: 38052714
[TBL] [Abstract][Full Text] [Related]
5. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt.
Lee EW; Kuei A; Saab S; Busuttil RW; Durazo F; Han SH; El-Kabany MM; McWilliams JP; Kee ST
World J Gastroenterol; 2016 Jul; 22(25):5780-9. PubMed ID: 27433091
[TBL] [Abstract][Full Text] [Related]
6. Impact of Malnutrition on Outcomes in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Insertion.
Chiang RS; Parish A; Niedzwiecki D; Kappus MR; Muir AJ
Dig Dis Sci; 2020 Nov; 65(11):3332-3340. PubMed ID: 31965391
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
Teng D; Zuo H; Liu L; Dong J; Ding L
Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
[TBL] [Abstract][Full Text] [Related]
8. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
9. Higher risk of in-hospital mortality and hepatic encephalopathy during weekend admission in Transjugular Intrahepatic Portosystemic Shunt procedure.
Li R; Lee S; Rienas W; Sarin S
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(7):102396. PubMed ID: 38876265
[TBL] [Abstract][Full Text] [Related]
10. Inpatient Cost Assessment of Transjugular Intrahepatic Portosystemic Shunt in the USA from 2001 to 2012.
Kuei A; Lee EW; Saab S; Busuttil RW; Durazo F; Han SH; ElKabany M; McWilliams JP; Kee ST
Dig Dis Sci; 2016 Oct; 61(10):2838-2846. PubMed ID: 27349987
[TBL] [Abstract][Full Text] [Related]
11. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.
Brand M; Prodehl L; Ede CJ
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001023. PubMed ID: 30378107
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.
Horhat A; Bureau C; Thabut D; Rudler M
United European Gastroenterol J; 2021 Mar; 9(2):203-208. PubMed ID: 32819214
[TBL] [Abstract][Full Text] [Related]
13. Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
Artru F; Moschouri E; Denys A
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101858. PubMed ID: 34999250
[TBL] [Abstract][Full Text] [Related]
14. Portosystemic Shunts: Stable Utilization and Improved Outcomes, Two Decades After the Transjugular Intrahepatic Portosystemic Shunt.
Perry BC; Kwan SW
J Am Coll Radiol; 2015 Dec; 12(12 Pt B):1427-33. PubMed ID: 26410348
[TBL] [Abstract][Full Text] [Related]
15. Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients.
He FL; Wang L; Yue ZD; Zhao HW; Liu FQ
World J Gastroenterol; 2014 Sep; 20(33):11835-9. PubMed ID: 25206289
[TBL] [Abstract][Full Text] [Related]
16. Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis.
He C; Lv Y; Wang Z; Guo W; Tie J; Li K; Niu J; Zuo L; Yu T; Yuan X; Chen H; Wang Q; Liu H; Bai W; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Wang J; Yin Z; Fan D; Han G
Dig Liver Dis; 2018 Dec; 50(12):1315-1323. PubMed ID: 29960900
[TBL] [Abstract][Full Text] [Related]
17. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
Wei J; Li H; Li C
J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
[TBL] [Abstract][Full Text] [Related]
18. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.
Simonetti RG; Perricone G; Robbins HL; Battula NR; Weickert MO; Sutton R; Khan S
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD000553. PubMed ID: 33089892
[TBL] [Abstract][Full Text] [Related]
19. Transjugular intrahepatic portosystemic shunt versus open splenectomy and esophagogastric devascularization for portal hypertension with recurrent variceal bleeding.
Su AP; Zhang ZD; Tian BL; Zhu JQ
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):169-175. PubMed ID: 28381381
[TBL] [Abstract][Full Text] [Related]
20. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
